iStock Rating

Press Releases
Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS
Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In March
Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate
Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013
The Reason It Trades, What's Moving CS, JAZZ, WNC and ALE
Free Research Report on Jazz Pharmaceuticals, Inc., Furiex Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., Prestige Brands Holdings, Inc. and Synta Pharmaceuticals, Inc.
The Real Story Behind LEE, CMVT, JAZZ and RENN
Key to Success, How to Profit: CLSN, GALE, KERX and JAZZ
Perfect Trade Setups, How to Play CLSN, GALE, KERX and JAZZ
Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference
Jazz Pharmaceuticals Announces Presentation Of Largest Safety Trial To Date Of Patients Treated With Erwinaze?
Key to Success, How to Profit: GALE, KERX and JAZZ
The Real Story Behind GALE, KERX and JAZZ
Jazz Pharmaceuticals Announces Issuance of Additional Xyrem? Patent
Jazz Pharmaceuticals Begins Clinical Trial of Intravenously Administered Erwinaze? In Patients with Acute Lymphoblastic Leukemia
Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
Jazz Pharmaceuticals Announces Support for National Campaign Designed to Curb Prescription Drug Abuse
Jazz Pharmaceuticals Announces Date to Release Third Quarter 2012 Results
Jazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda
/C O R R E C T I O N -- Jazz Pharmaceuticals/
Jazz Pharmaceuticals Announces Issuance of New Formulation Patent for Xyrem?
Jazz Pharmaceuticals Announces Participation At The 2012 Morgan Stanley Global Healthcare Conference In New York On September 11
Jazz Pharmaceuticals Enters Definitive Agreement to Sell its Women's Health Business to Meda
Catherine Sohn Elected To Jazz Pharmaceuticals Board Of Directors
Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
"AWAKEN" Survey Finds Only 50 Percent of Americans Understand Significant Health Impact of Narcolepsy, and Many Physicians Not Comfortable Diagnosing the Sleep Disorder
Jazz Pharmaceuticals Announces Presentation At The Jefferies 2012 Global Healthcare Conference In New York On June 7
A Forward Look, the Year Ahead - Featured Research on Jazz Pharmaceuticals and Human Genome Sciences
Critical Alerts For Macy's, Avis, Rackspace, Stone Energy, and Jazz Pharmaceuticals Released By InvestorsObserver
Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Wake Up Narcolepsy and Jazz Pharmaceuticals Announce Swinging for Sleep to Raise Funds for Narcolepsy Awareness
Jazz Pharmaceuticals Announces Public Offering of Ordinary Shares by Selling Shareholders
Jazz Pharmaceuticals Reports 2011 Full Year and Fourth Quarter Financial Results
Jazz Pharmaceuticals to Announce 2011 Full Year and Fourth Quarter Financial Results on February 27, 2012
Jazz Pharmaceuticals Announces Stockholder Vote in Favor of Transaction With Azur Pharma Limted
Market Considerations in Europe Outlook - Featured Research on Jazz Pharmaceuticals, Inc. and Dendreon Corporation
Europe Situation Forecasts Change - Report Highlights Jazz Pharmaceuticals, Inc. and JA Solar Holdings Co., Ltd. (ADR)
Jazz Pharmaceuticals Announces Presentations at Investor Conferences in November
Jazz Pharmaceuticals Announces Third Quarter 2011 Results Conference Call on November 1
Jazz Pharmaceuticals Appoints Head of Research and Development
Jazz Pharmaceuticals and Azur Pharma Agree to Combine to Form Jazz Pharmaceuticals plc
Factors Moving Markets, Worldwide View - Equity Research on Transcept Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals Announces Presentation at the UBS Global Life Sciences Conference in New York on September 20
Effect of Today's Deadline, Market Dynamics to Consider - Research Report on Jazz Pharmaceuticals, Inc. and Forest Laboratories, Inc.
Jazz Pharmaceuticals Announces Presentation at the Jefferies 2011 Global Healthcare Conference in New York on June 8
Jazz Pharmaceuticals Announces First Quarter 2011 Financial Results
Jazz Pharmaceuticals Announces First Quarter 2011 Results Conference Call on May 3
Jazz Pharmaceuticals to Present at Upcoming Investor Conferences
Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results
Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference in San Francisco on January 12